Lafadofensine

Overview of the drug Lafadofensine

Chemical structure of Lafadofensine

Lafadofensine is a chemical compound that was investigated for its potential use as a pharmaceutical drug in the treatment of depression. It belongs to a class of drugs known as norepinephrine-dopamine reuptake inhibitors (NDRIs), which function by inhibiting the reuptake of the neurotransmitters norepinephrine and dopamine in the brain, thereby increasing their levels and activity.

Pharmacology

Lafadofensine acts primarily as a norepinephrine-dopamine reuptake inhibitor. This mechanism of action is similar to that of other NDRIs, such as bupropion. By blocking the reuptake of norepinephrine and dopamine, lafadofensine increases the concentration of these neurotransmitters in the synaptic cleft, which can enhance mood and alleviate symptoms of depression.

Development and Research

Lafadofensine was developed in the late 1990s and early 2000s. It was studied in clinical trials to assess its efficacy and safety in treating major depressive disorder. However, despite initial promise, the development of lafadofensine was eventually discontinued. The reasons for discontinuation often include insufficient efficacy, adverse side effects, or strategic business decisions by the developing company.

Chemical Properties

Lafadofensine is a synthetic compound with a specific chemical structure that allows it to interact with the norepinephrine and dopamine transporters in the brain. The chemical structure of lafadofensine is depicted in the image to the right.

Potential Side Effects

As with many drugs affecting neurotransmitter systems, lafadofensine was associated with a range of potential side effects. These could include insomnia, dry mouth, nausea, and anxiety. The safety profile of lafadofensine was a critical factor in its clinical evaluation.

Related pages

• Norepinephrine-dopamine reuptake inhibitor
• Major depressive disorder
• Bupropion
• Neurotransmitter